Landscapes / Companies
Ipsen not checked
FollowEvery new trial, moved date and filing, and a Monday email
Furthest along
3 approved
2 in Phase 3
Drugs
10
in active trials · 40 in all
Trials
21 active
88 since 2021
Drugs10
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Peroxisome proliferator-activated receptor agonist |
Approved | 17 Dec 2026soonPhase 3 trial completes | |||
| Next date | 17 Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | Primary Sclerosing Cholangitis, Primary Biliary Cirrhosis and 2 more | ||||
| Open drug page | |||||
AbobotulinumtoxinAnot checked |
Acetylcholine release Inhibitor; neuromuscular blocker |
Approved | 19 Aug 2027Phase 1/2 trial completes | ||
| Next date | 19 Aug 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Spasticity, Moderate to Severe Upper Facial Lines and 2 more | ||||
| Open drug page | |||||
Kinase inhibitor |
Day One Biopharmaceuticals |
Approved | 31 Jul 2030Phase 1 trial completes | ||
| How it works | Blocks a kinase | ||||
| Next date | 31 Jul 2030 · Phase 1 trial completes | ||||
| Also tested for | Low-grade Glioma | ||||
| Open drug page | |||||
— |
Phase 3 | 15 Dec 2026soonPhase 3 trial completes | |||
| Next date | 15 Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | Moderate to Severe Glabellar Lines, Spasticity and 4 more | ||||
| Open drug page | |||||
— |
ImCheck Therapeutics, an Ipsen company |
Phase 2/3 | 15 Oct 2027Phase 1/2 trial completes | ||
| Next date | 15 Oct 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Solid Tumor, Adult, Hematopoietic/Lymphoid Cancer and 2 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | 20 Mar 2028Phase 1/2 trial completes | |||
| Next date | 20 Mar 2028 · Phase 1/2 trial completes | ||||
| Also tested for | Melanoma, Head and Neck Squamous Cell Carcinoma and 3 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | 4 Apr 2028Phase 1/2 trial completes | |||
| Next date | 4 Apr 2028 · Phase 1/2 trial completes | ||||
| Also tested for | Advanced Solid Tumor | ||||
| Open drug page | |||||
— |
Phase 1/2 | 30 Oct 2028Phase 1/2 trial completes | |||
| Next date | 30 Oct 2028 · Phase 1/2 trial completes | ||||
| Also tested for | Locally Advanced Solid Tumor, Metastatic Solid Tumor | ||||
| Open drug page | |||||
IPN60350not checked |
— |
Phase 1/2 | 28 Jun 2030Phase 1/2 trial completes | ||
| Next date | 28 Jun 2030 · Phase 1/2 trial completes | ||||
| Also tested for | Neoplasms, Neoplasm Metastasis and 2 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | 14 Jul 2032Phase 1/2 trial completes | |||
| Next date | 14 Jul 2032 · Phase 1/2 trial completes | ||||
| Also tested for | Advanced Solid Tumor, Metastatic Solid Tumor | ||||
| Open drug page | |||||
No drugs match “”.
About
- No active trial
- 30 other drugs
- SEC filings
- None: it does not file with the US SEC
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 Industry-sponsored drug trials since 2021